Ms. Duncan most recently served as the Chief Financial Officer of Intercept Pharmaceuticals Inc., a biopharmaceutical company, from 2009 to June 2016. Prior to Intercept, Ms. Duncan served as Chief Financial Officer of DOV Pharmaceutical, Inc., another biopharmaceutical company, from 2001 to 2006 and as its Chief Executive Officer and a member of its Board of Directors from 2007 to 2009.

Ms. Duncan currently serves on the Board of Directors, Audit Committee and Nominating and Corporate Governance Committee of Atea Pharmaceuticals, Inc. and Jounce Therapeutics, Inc. each a biopharmaceutical company. She also serves on the Boards of Directors and Audit Committees of Adaptimmune Therapeutics plc, ObsEva SA and Ovid Therapeutics, Inc., all biopharmaceutical companies. 

Ms. Duncan holds an M.B.A. from the Wharton School of Business and a B.S. from Louisiana State University.